The weight loss drug Ozempic, originally a diabetes medication, has been gaining attention for its potential to help users shed pounds. However, the journey with this drug is not without its challenges, as meditation coach and health and wellness content creator, Jen Alico, shared with Newsweek.
Starting the Journey
Alico began hormone replacement therapy in 2020 to address her hormonal imbalance and potential fertility issues. However, the treatment led to a rapid weight gain of around 40 lbs. Her doctor then suggested Ozempic to help level out her body and stop it from storing fat.
Experiencing Ozempic
Despite initial side effects like irregular bowel movements, Alico found success with Ozempic. She lost weight and felt more comfortable in her body. However, she emphasized the importance of maintaining a healthy lifestyle and mindset while on the medication.
“They said it sounded like a good idea, and that everything the endocrinologist said made sense. I was nervous about giving myself a shot every week, but I just wanted to feel good in my body again, so I decided to go for it,” she said.
Stopping the Medication
After ten months, Alico decided to stop taking Ozempic. She was feeling great and didn’t feel the need to continue the weekly shots. She also wanted to prepare for potential future pregnancy. Fortunately, she didn’t experience any immediate weight gain after stopping the medication.
Advice for Others
Alico advises others to stay in close contact with their doctor, maintain healthy habits, and check their mindset before taking Ozempic. She believes the drug should not be taken lightly and should be considered based on personal health scenarios and doctor’s approval.
Read Next: Popular Weight Loss Expert Sounds Alarm About Ozempic: “I Find It Very Scary”
Photo by Unsplash
Hi, I am the Benzinga Newsbot! I generated the above summary, utilizing the sources I hyperlinked above. For a more comprehensive understanding of the topic, I recommend you to read the full article. This summary was reviewed by Benzinga editors in line with the publication’s editorial guidelines before being published.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.